§ Federal grant opportunity · HT942526ALSRPCOBA

    DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

    Jamie Shortall Grant Officer is accepting applications for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award. The deadline is September 30, 2026 and the published award range is Award amount not published.

    Key facts

    Funder
    Jamie Shortall Grant Officer
    Application deadline
    September 30, 2026
    Award range
    Award amount not published
    Eligibility
    Eligibility criteria are published in the funding opportunity announcement.
    Geography
    United States
    Focus areas
    Research
    Opportunity number
    HT942526ALSRPCOBA

    Program overview

    Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from Jamie Shortall Grant Officer.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before September 30, 2026, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.